Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

You may be eligible if

• Confirmed diagnosis of malignant melanoma
• Measurable disease
• Granulocytes ≥1,500/µl, Platelets ≥100,000/µl, Creatinine ≤ULN, Bilirubin ≤1.5 mg/dl, AST ≤2.5 x ULN
• No prior treatment with other camptothecin drug.
• ≥ 21 days since completion of prior chemotherapy, ≥6 weeks since prior Mitomycin-C
• ECOG Performance Status 0-1
• Negative pregnancy test for female patients